Waiting times disparities for medication-assisted therapy among opioid use disorder treatment population in the United States.

Opioid use disorder (OUD) treatment has been described as beneficial in reducing the burden of OUD and its related complications. Thus far, there is a paucity of literature on the time-to-treatment differences from the period of seeking treatment to when the patient starts treatment. Hence, it is deemed a form of barrier to the accessibility of OUD treatment programs. We aim to study the relationship between accessibility for medication-assisted treatment and the disparity concerning days waiting to enter OUD treatment. The treatment episode data set (TEDS) was utilized for this study. The full sample of 2018 TEDS-D (N = 382,547) is representative of OUD patients that utilized SUD treatment facilities within the 50 states of the United States. Univariate and multivariable logistic analysis of the independent variables, and other covariates with the dependent variables were explored to estimate the adjusted odds ratio relationship. Medication-assisted opioid therapy use among respondents was significantly different with waiting 1-7 days [AOR = 1.321 (95% CI = 1.248-1.400)] and >7 days [AOR = 0.729 (95% CI = 0.665-0.799)] to enter OUD treatment compared to waiting for less than a day. Among adults seeking OUD treatment admissions, our study showed that waiting times vary with MAT use as there was early entry compared to >1week wait time. Similarly, significant associations were reported across different sociodemographic attributes except for biological sex.

Two Cases of Persistent Complex Bereavement Disorder Diagnosed in the Acute Inpatient Unit.

Pathological grief has been noted to have considerable adverse effects on affected individuals. In the DSM-5, the diagnosis of complicated grief is included under conditions for further study as Persistent Complex Bereavement Disorder (PCBD). PCBD can be easily missed because it is a relatively new and developing diagnosis. It can also be overlooked when it is comorbid with more common psychiatric disorders. We present 2 patients with PCBD diagnosed in the inpatient unit, while the patients were admitted for comorbid disorders. PCBD contributed immensely to both patients' suffering and decline in functioning. This report highlights the presentation, diagnoses, and management of these patients. We theorize that paying attention to separation distress, reactive distress to loss, and identity disruption in individuals who have been bereaved for over 12 months will enhance treatment specificity and lead to better patient outcomes.

COVID-19 Pandemic and Uptake in Suicide Attempt Among Young People of Minority Population: A Case Series.

The first case of coronavirus disease 2019 (COVID-19) was reported in Wuhan China on December 31, 2019. COVID-19 was declared a global pandemic on March 11, 2020. To reduce the spread of this virus, the World Health Organization (WHO) and the Center for Disease Control (CDC) recommended self and mandatory quarantine of exposed individuals and self-isolation. However, the psychological impact of this pandemic includes new onset or worsening of existing mental illnesses which include but are not limited to anxiety, depression from social isolation, eating disorders, and uptake in suicidality either in isolation or part of mental illness symptomatology. In the USA, suicide is the second leading cause of death among people aged 10 - 34 years while globally, it is the second cause of death among people aged 15 - 29 years. The authors present a case of two young women of minority population with no prior psychiatric illnesses who presented to the psychiatry emergency room with suicidal attempts due to COVID-19 pandemic-related psychosocial stressors.